GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (LTS:0R6U) » Definitions » Retained Earnings

4SC AG (LTS:0R6U) Retained Earnings : €-244.61 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is 4SC AG Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. 4SC AG's retained earnings for the quarter that ended in Dec. 2023 was €-244.61 Mil.

4SC AG's quarterly retained earnings declined from Dec. 2022 (€-236.37 Mil) to Jun. 2023 (€-241.04 Mil) and declined from Jun. 2023 (€-241.04 Mil) to Dec. 2023 (€-244.61 Mil).

4SC AG's annual retained earnings declined from Dec. 2021 (€-222.01 Mil) to Dec. 2022 (€-236.37 Mil) and declined from Dec. 2022 (€-236.37 Mil) to Dec. 2023 (€-244.61 Mil).


4SC AG Retained Earnings Historical Data

The historical data trend for 4SC AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG Retained Earnings Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -191.44 -210.43 -222.01 -236.37 -244.61

4SC AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -222.01 -233.35 -236.37 -241.04 -244.61

4SC AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


4SC AG  (LTS:0R6U) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


4SC AG (LTS:0R6U) Business Description

Traded in Other Exchanges
Address
Fraunhoferstraße 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG (LTS:0R6U) Headlines

No Headlines